Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience

M. Chun, P. McKeough, A. Wu, D. Kasdon, Deborah O Heros, H. Chang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The treatment results of 37 patients with malignant brain neoplasms treated with a computed-tomography-guided stereotactic iridium-192 implant are reviewed. Of these, 29 patients with high-grade gliomas (20 with glioblastoma multiform (GBM), nine with anaplastic astrocytoma (AA)) received an implant as part of their initial management. The median survival was 14.5 and 15.5 months in the patients with previously untreated GBM and AA, respectively. In those patients with recurrent tumour after external-beam irradiation, durable local control over a year was achieved with implantation. Increasing the total tumour dose from 120 to 160 Gy did not improve survival or local control. Karnofsky Performance Status (KPS) was used as an indicator of quality of life and was seen to decrease with a median interval of 8.5 months following treatment. No severe complications were noted in the entire group of patients treated with this implant procedure.

Original languageEnglish
Pages (from-to)158-162
Number of pages5
JournalBritish Journal of Radiology
Volume62
Issue number734
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Iridium
Brain Neoplasms
Astrocytoma
Glioblastoma
Karnofsky Performance Status
Survival
Glioma
Neoplasms
Tomography
Quality of Life
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Chun, M., McKeough, P., Wu, A., Kasdon, D., Heros, D. O., & Chang, H. (1989). Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience. British Journal of Radiology, 62(734), 158-162.

Interstitial iridium-192 implantation for malignant brain tumours. Part II : Clinical experience. / Chun, M.; McKeough, P.; Wu, A.; Kasdon, D.; Heros, Deborah O; Chang, H.

In: British Journal of Radiology, Vol. 62, No. 734, 01.01.1989, p. 158-162.

Research output: Contribution to journalArticle

Chun, M, McKeough, P, Wu, A, Kasdon, D, Heros, DO & Chang, H 1989, 'Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience', British Journal of Radiology, vol. 62, no. 734, pp. 158-162.
Chun M, McKeough P, Wu A, Kasdon D, Heros DO, Chang H. Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience. British Journal of Radiology. 1989 Jan 1;62(734):158-162.
Chun, M. ; McKeough, P. ; Wu, A. ; Kasdon, D. ; Heros, Deborah O ; Chang, H. / Interstitial iridium-192 implantation for malignant brain tumours. Part II : Clinical experience. In: British Journal of Radiology. 1989 ; Vol. 62, No. 734. pp. 158-162.
@article{2fbfbb3fb0b34441b4f4bb2e07d0c6a6,
title = "Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience",
abstract = "The treatment results of 37 patients with malignant brain neoplasms treated with a computed-tomography-guided stereotactic iridium-192 implant are reviewed. Of these, 29 patients with high-grade gliomas (20 with glioblastoma multiform (GBM), nine with anaplastic astrocytoma (AA)) received an implant as part of their initial management. The median survival was 14.5 and 15.5 months in the patients with previously untreated GBM and AA, respectively. In those patients with recurrent tumour after external-beam irradiation, durable local control over a year was achieved with implantation. Increasing the total tumour dose from 120 to 160 Gy did not improve survival or local control. Karnofsky Performance Status (KPS) was used as an indicator of quality of life and was seen to decrease with a median interval of 8.5 months following treatment. No severe complications were noted in the entire group of patients treated with this implant procedure.",
author = "M. Chun and P. McKeough and A. Wu and D. Kasdon and Heros, {Deborah O} and H. Chang",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "62",
pages = "158--162",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "734",

}

TY - JOUR

T1 - Interstitial iridium-192 implantation for malignant brain tumours. Part II

T2 - Clinical experience

AU - Chun, M.

AU - McKeough, P.

AU - Wu, A.

AU - Kasdon, D.

AU - Heros, Deborah O

AU - Chang, H.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The treatment results of 37 patients with malignant brain neoplasms treated with a computed-tomography-guided stereotactic iridium-192 implant are reviewed. Of these, 29 patients with high-grade gliomas (20 with glioblastoma multiform (GBM), nine with anaplastic astrocytoma (AA)) received an implant as part of their initial management. The median survival was 14.5 and 15.5 months in the patients with previously untreated GBM and AA, respectively. In those patients with recurrent tumour after external-beam irradiation, durable local control over a year was achieved with implantation. Increasing the total tumour dose from 120 to 160 Gy did not improve survival or local control. Karnofsky Performance Status (KPS) was used as an indicator of quality of life and was seen to decrease with a median interval of 8.5 months following treatment. No severe complications were noted in the entire group of patients treated with this implant procedure.

AB - The treatment results of 37 patients with malignant brain neoplasms treated with a computed-tomography-guided stereotactic iridium-192 implant are reviewed. Of these, 29 patients with high-grade gliomas (20 with glioblastoma multiform (GBM), nine with anaplastic astrocytoma (AA)) received an implant as part of their initial management. The median survival was 14.5 and 15.5 months in the patients with previously untreated GBM and AA, respectively. In those patients with recurrent tumour after external-beam irradiation, durable local control over a year was achieved with implantation. Increasing the total tumour dose from 120 to 160 Gy did not improve survival or local control. Karnofsky Performance Status (KPS) was used as an indicator of quality of life and was seen to decrease with a median interval of 8.5 months following treatment. No severe complications were noted in the entire group of patients treated with this implant procedure.

UR - http://www.scopus.com/inward/record.url?scp=0024587517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024587517&partnerID=8YFLogxK

M3 - Article

C2 - 2538197

AN - SCOPUS:0024587517

VL - 62

SP - 158

EP - 162

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 734

ER -